DNASE1L3 regulation by transcription factor FOXP2 affects the proliferation, migration, invasion and tube formation of lung adenocarcinoma

Meng,Fanlu; Yang,Xue; Xiao,Ping

doi:10.3892/etm.2022.11771

DNASE1L3 regulation by transcription factor FOXP2 affects the proliferation, migration, invasion and tube formation of lung adenocarcinoma

Authors:
- Fanlu Meng
- Xue Yang
- Ping Xiao
View Affiliations

Affiliations: Department of Medical Oncology, Tianjin Medical University General Hospital, Heping, Tianjin 300052, P.R. China
Published online on: December 19, 2022 https://doi.org/10.3892/etm.2022.11771
Article Number: 72
Copyright: © Meng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung adenocarcinoma (LUAD) is prone to bone metastasis, resulting in poor prognosis. The present study aimed to detect the expression of deoxyribonuclease 1‑like 3 (DNASE1L3) and forkhead‑box P2 (FOXP2) in LUAD cells to investigate the role of DNASE1L3 in the regulation of proliferation, migration, invasion and tube formation of LUAD cells and how FOXP2 affects DNASE1L3 expression. The expression of DNASE1L3 and FOXP2 in LUAD cells was analyzed by reverse transcription‑quantitative PCR (RT‑qPCR) and western blotting. The transfection efficiency of DNASE1L3 overexpression plasmids, FOXP2 overexpression or interference plasmids into A549 cells was also confirmed by RT‑qPCR and western blotting. The viability, proliferation, migration and invasion and tube formation of LUAD cells following transfection was in turn detected by MTT, EdU staining, wound healing, Transwell and tube formation assay. The expression of proteins associated with epithelial‑mesenchymal transformation and tube formation was detected by western blotting. Binding between DNASE1L3 and FOXP2 was confirmed by dual‑luciferase reporter assay and chromatin immunoprecipitation. Gene Expression Profiling Interactive Analysis database predicted that underexpression of DNASE1L3 in LUAD was associated with poor prognosis. DNASE1L3 expression was decreased in LUAD cells and overexpression of DNASE1L3 inhibited the proliferation, migration, invasion and tube formation of LUAD cells. Transcription factor FOXP2 positively regulated DNASE1L3 transcription in LUAD cells. FOXP2 was also underexpressed in LUAD cells and downregulation of FOXP2 promoted proliferation, migration, invasion and tube formation of LUAD cells, which was reversed by overexpression of DNASE1L3. In conclusion, DNASE1L3 was positively regulated by transcription factor FOXP2 and overexpression inhibited proliferation, migration, invasion and tube formation of LUAD cells.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI View Article : Google Scholar
2	Reck M and Rabe KF: Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med. 377:849–861. 2017.PubMed/NCBI View Article : Google Scholar
3	Qu BL, Cai BN, Yu W, Liu F, Huang YR, Ju ZJ, Wang XS, Ou GM and Feng LC: Radiotherapy effects on brain/bone metastatic adenocarcinoma lung cancer and the importance of EGFR mutation test. Neoplasma. 63:158–162. 2016.PubMed/NCBI View Article : Google Scholar
4	Wang Y, Yang N, Zhang Y, Li L, Han R, Zhu M, Feng M, Chen H, Lizaso A, Qin T, et al: Effective treatment of lung adenocarcinoma harboring EGFR-activating mutation, T790M, and cis-C797S triple mutations by brigatinib and cetuximab combination therapy. J Thorac Oncol. 15:1369–1375. 2020.PubMed/NCBI View Article : Google Scholar
5	Marinelli D, Mazzotta M, Scalera S, Terrenato I, Sperati F, D'Ambrosio L, Pallocca M, Corleone G, Krasniqi E, Pizzuti L, et al: KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. Ann Oncol. 31:1746–1754. 2020.PubMed/NCBI View Article : Google Scholar
6	Napirei M, Wulf S, Eulitz D, Mannherz HG and Kloeckl T: Comparative characterization of rat deoxyribonuclease 1 (Dnase1) and murine deoxyribonuclease 1-like 3 (Dnase1l3). Biochem J. 389:355–364. 2005.PubMed/NCBI View Article : Google Scholar
7	Sisirak V, Sally B, D'Agati V, Martinez-Ortiz W, Özçakar ZB, David J, Rashidfarrokhi A, Yeste A, Panea C, Chida AS, et al: Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity. Cell. 166:88–101. 2016.PubMed/NCBI View Article : Google Scholar
8	Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, et al: The consensus coding sequences of human breast and colorectal cancers. Science. 314:268–274. 2006.PubMed/NCBI View Article : Google Scholar
9	Xiao Y, Yang K, Liu P, Ma D, Lei P and Liu Q: Deoxyribonuclease 1-like 3 inhibits hepatocellular carcinoma progression by inducing apoptosis and reprogramming glucose metabolism. Int J Biol Sci. 18:82–95. 2022.PubMed/NCBI View Article : Google Scholar
10	Guo D, Ma D, Liu P, Lan J, Liu Z and Liu Q: DNASE1L3 arrests tumor angiogenesis by impairing the senescence-associated secretory phenotype in response to stress. Aging (Albany NY). 13:9874–9899. 2021.PubMed/NCBI View Article : Google Scholar
11	Liu J, Yi J, Zhang Z, Cao D, Li L and Yao Y: Deoxyribonuclease 1-like 3 may be a potential prognostic biomarker associated with immune infiltration in colon cancer. Aging (Albany NY). 13:16513–16526. 2021.PubMed/NCBI View Article : Google Scholar
12	Deng Z, Xiao M, Du D, Luo N, Liu D, Liu T, Lian D and Peng J: DNASE1L3 as a prognostic biomarker associated with immune cell infiltration in cancer. Onco Targets Ther. 14:2003–2017. 2021.PubMed/NCBI View Article : Google Scholar
13	Chen J, Ding J, Huang W, Sun L, Chen J, Liu Y, Zhan Q, Gao G, He X, Qiu G, et al: DNASE1L3 as a novel diagnostic and prognostic biomarker for lung adenocarcinoma based on data mining. Front Genet. 12(699242)2021.PubMed/NCBI View Article : Google Scholar
14	Wu J, Liu P, Tang H, Shuang Z, Qiu Q, Zhang L, Song C, Liu L, Xie X and Xiao X: FOXP2 promotes tumor proliferation and metastasis by targeting GRP78 in triple-negative breast cancer. Curr Cancer Drug Targets. 18:382–389. 2018.PubMed/NCBI View Article : Google Scholar
15	Song XL, Tang Y, Lei XH, Zhao SC and Wu ZQ: miR-618 inhibits prostate cancer migration and invasion by targeting FOXP2. J Cancer. 8:2501–2510. 2017.PubMed/NCBI View Article : Google Scholar
16	Ren T, Liu C, Hou J and Shan F: Hsa_circ_0043265 suppresses proliferation, metastasis, EMT and promotes apoptosis in non-small cell lung cancer through miR-25-3p/FOXP2 pathway. Onco Targets Ther. 13:3867–3880. 2020.PubMed/NCBI View Article : Google Scholar
17	Li ZY, Zhang ZZ, Bi H, Zhang QD, Zhang SJ, Zhou L, Zhu XQ and Zhou J: Upregulated microRNA-671-3p promotes tumor progression by suppressing forkhead box P2 expression in non-small-cell lung cancer. Mol Med Rep. 20:3149–3159. 2019.PubMed/NCBI View Article : Google Scholar
18	Tang Z, Kang B, Li C, Chen T and Zhang Z: GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 47:W556–W560. 2019.PubMed/NCBI View Article : Google Scholar
19	Zhu Y, Li B, Xu G, Han C and Xing G: lncRNA MIR4435-2HG promotes the progression of liver cancer by upregulating B3GNT5 expression. Mol Med Rep. 25(38)2022.PubMed/NCBI View Article : Google Scholar
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
21	Zagryazhskaya A, Gyuraszova K and Zhivotovsky B: Cell death in cancer therapy of lung adenocarcinoma. Int J Dev Biol. 59:119–129. 2015.PubMed/NCBI View Article : Google Scholar
22	Nasim F, Sabath BF and Eapen GA: Lung cancer. Med Clin North Am. 103:463–473. 2019.PubMed/NCBI View Article : Google Scholar
23	O'Leary K, Shia A and Schmid P: Epigenetic regulation of EMT in non-small cell lung cancer. Curr Cancer Drug Targets. 18:89–96. 2018.PubMed/NCBI View Article : Google Scholar
24	Dongre A and Weinberg RA: New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 20:69–84. 2019.PubMed/NCBI View Article : Google Scholar
25	Tan-Garcia A, Lai F, Sheng Yeong JP, Irac SE, Ng PY, Msallam R, Tatt Lim JC, Wai LE, Tham CYL, Choo SP, et al: Liver fibrosis and CD206⁺ macrophage accumulation are suppressed by anti-GM-CSF therapy. JHEP Rep. 2(100062)2020.PubMed/NCBI View Article : Google Scholar
26	Baek SH, Ko JH, Lee JH, Kim C, Lee H, Nam D, Lee J, Lee SG, Yang WM, Um JY, et al: Ginkgolic acid inhibits invasion and migration and TGF-β-induced EMT of lung cancer cells through PI3K/Akt/mTOR inactivation. J Cell Physiol. 232:346–354. 2017.PubMed/NCBI View Article : Google Scholar
27	Wu JB, Tang YL and Liang XH: Targeting VEGF pathway to normalize the vasculature: An emerging insight in cancer therapy. Onco Targets Ther. 11:6901–6909. 2018.PubMed/NCBI View Article : Google Scholar
28	Frezzetti D, Gallo M, Maiello MR, D'Alessio A, Esposito C, Chicchinelli N, Normanno N and De Luca A: VEGF as a potential target in lung cancer. Expert Opin Ther Targets. 21:959–966. 2017.PubMed/NCBI View Article : Google Scholar
29	Cuiffo BG, Campagne A, Bell GW, Lembo A, Orso F, Lien EC, Bhasin MK, Raimo M, Hanson SE, Marusyk A, et al: MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis. Cell Stem Cell. 15:762–774. 2014.PubMed/NCBI View Article : Google Scholar
30	Yan X, Zhou H and Zhang T, Xu P, Zhang S, Huang W, Yang L, Gu X, Ni R and Zhang T: Downregulation of FOXP2 promoter human hepatocellular carcinoma cell invasion. Tumour Biol. 36:9611–9619. 2015.PubMed/NCBI View Article : Google Scholar
31	Jia WZ, Yu T, An Q, Yang H, Zhang Z, Liu X and Xiao G: MicroRNA-190 regulates FOXP2 genes in human gastric cancer. Onco Targets Ther. 9:3643–3651. 2016.PubMed/NCBI View Article : Google Scholar
32	Yu Z, Lin X, Tian M and Chang W: microRNA-196b promotes cell migration and invasion by targeting FOXP2 in hepatocellular carcinoma. Oncol Rep. 39:731–738. 2018.PubMed/NCBI View Article : Google Scholar
33	Diao H, Ye Z and Qin R: miR-23a acts as an oncogene in pancreatic carcinoma by targeting FOXP2. J Investig Med. 66:676–683. 2018.PubMed/NCBI View Article : Google Scholar
34	He Q, Zhao L, Liu Y, Liu X, Zheng J, Yu H, Cai H, Ma J, Liu L, Wang P, et al: circ-SHKBP1 regulates the angiogenesis of U87 glioma-exposed endothelial cells through miR-544a/FOXP1 and miR-379/FOXP2 pathways. Mol Ther Nucleic Acids. 10:331–348. 2018.PubMed/NCBI View Article : Google Scholar